Paul Grayson
Director/Board Member bei SKYE BIOSCIENCE, INC.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Paul A.
Grayson is the founder of Senomyx, Inc. (founded in 1998) and Fate Therapeutics, Inc. (founded in 2007).
He held the title of President & Chief Executive Officer at Senomyx, Inc. from 1998 to 2003 and at Fate Therapeutics, Inc. from 2008 to 2011.
Currently, Mr. Grayson holds the position of President & Chief Executive Officer at RuiYi, Inc. (China), President & Chief Executive Officer at Radionetics Oncology, Inc. (since 2024), Director at Skye Bioscience, Inc. (since 2023), and Member at Aurora Biosciences Corp.
In the past, Mr. Grayson served as President, Chief Executive Officer & Director at Bird Rock Bio Sub, Inc. from 2011 to 2023.
He also held positions such as President, Chief Executive Officer & Director at Tentarix Biotherapeutics, Inc., Chairman at Naviscan, Inc., Chairman at CalciMedica, Inc. (US), Managing Director at Sanderling Management CO LLC from 2003 to 2008, and Director at Chimerix, Inc., Ren Pharmaceuticals, Inc., Apoptos, Inc., Receptos LLC, TempestTx, Inc., Progenitor Labs Ltd., and Contineum Therapeutics, Inc. .
Mr. Grayson's education includes an undergraduate degree from the University of California, Los Angeles (1986) and an MBA from the University of California, Irvine (1989).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SKYE BIOSCIENCE, INC.
1,23% | 29.02.2024 | 346 252 ( 1,23% ) | 5 Mio $ | 31.03.2024 |
Aktive Positionen von Paul Grayson
| Unternehmen | Position | Beginn |
|---|---|---|
| SKYE BIOSCIENCE, INC. | Director/Board Member | 18.08.2023 |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Corporate Officer/Principal | 21.04.2010 |
RuiYi, Inc. (China)
 RuiYi, Inc. (China) BiotechnologyHealth Technology Part of 5AM Venture Management LLC, RuiYi, Inc. (China) is a Chinese company that develops biologic therapies. The private company is based in Pudong, China. The CEO of the company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio Sub, Inc., part of 5AM Venture Management LLC from December 11, 2023 on March 22, 2012. | Chief Executive Officer | - |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Chief Executive Officer | 03.01.2024 |
Ehemalige bekannte Positionen von Paul Grayson
| Unternehmen | Position | Ende |
|---|---|---|
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 01.01.2024 |
| CONTINEUM THERAPEUTICS, INC. | Director/Board Member | 01.11.2023 |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Chief Executive Officer | 18.08.2023 |
| FATE THERAPEUTICS, INC. | Chief Executive Officer | 21.02.2011 |
Sanderling Management CO LLC
 Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Corporate Officer/Principal | 01.04.2008 |
Ausbildung von Paul Grayson
| University of California, Los Angeles | Undergraduate Degree |
| University of California, Irvine | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 16 |
|---|---|
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Senomyx, Inc.
 Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
Sanderling Management CO LLC
Sanderling Management CO LLC Investment ManagersFinance Sanderling Management CO LLC (Sanderling Ventures) is a venture capital firm founded in 1979 by Robert G. McNeil. The firm is headquartered in San Mateo, California. | Finance |
Naviscan, Inc.
 Naviscan, Inc. Electronic Production EquipmentElectronic Technology Naviscan, Inc. develops, manufactures, and markets organ molecular imaging scanners. The company was founded by Irving Weinberg on January 31, 2006 and is headquartered in San Diego, CA. | Electronic Technology |
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Health Technology |
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Health Technology |
Apoptos, Inc.
 Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Health Technology |
RuiYi, Inc. (China)
RuiYi, Inc. (China) BiotechnologyHealth Technology Part of 5AM Venture Management LLC, RuiYi, Inc. (China) is a Chinese company that develops biologic therapies. The private company is based in Pudong, China. The CEO of the company is Paul A. Grayson. RuiYi, Inc. (China was acquired by Bird Rock Bio Sub, Inc., part of 5AM Venture Management LLC from December 11, 2023 on March 22, 2012. | Health Technology |
Progenitor Labs Ltd.
 Progenitor Labs Ltd. Pharmaceuticals: MajorHealth Technology Progenitor Labs Ltd. develops drugs to regenerate specific tissues of the human body in response to injury, disease, and ageing. Its products include ProScreen and CombiCult. The company was founded by Yen Choo on February 12, 2010 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
| Skye Bioscience, Inc. | |
| Tentarix Biotherapeutics, Inc. | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
